GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Lab] QYB orfo — Medutest came back 99.3% against a claimed 99.0% — 31 comments in the full submission. View in context.
694
c/orforglipron·submitted 2 years ago by u/ravi_sandvik

[Lab] QYB orfo — Medutest came back 99.3% against a claimed 99.0%

Trial Databranch of 6 comments

Short version of the title, which is already short: QYB orfo — Medutest came back 99.3% against a claimed 99.0%. Longer version underneath. Numbers, in the order they matter: 99.3% and 99.0%. The analytical point, which this board keeps getting wrong by importing habits from the peptide side. For a peptide, purity is…

Read the full submission and all 31 comments →

This branch

6 comments, started 2 years ago
u/joaquin_trevino42 points·2 years ago

Oral semaglutide is a peptide co-formulated with an absorption enhancer and carries food and water timing requirements. A small molecule does not have that constraint, which is the practical distinction.

replysharereportpermalink
u/phase_two_peteMOD32 points·2 years ago

Left up. It is careful about what is peptide and what is not, which is more than most threads here manage.

replysharereportpermalink
u/ravi_sandvikOP24 points·2 years ago

Is that from the publication or the press release?

replysharereportpermalink
u/maren_sorensen25 points·2 years ago

Small fix — the two programme names got swapped upthread and it changes which population the figure came from.

replysharereportpermalink
u/ravi_sandvikOP10 points·2 years ago

Milligram-for-milligram comparison with an injectable peptide is not meaningful and I should not have made it.

replysharereportpermalink
u/chidi_yilmaz0 points·2 years ago

Small fix — the two programme names got swapped upthread and it changes which population the figure came from.

Disagreeing with this bit: daily dosing is a different adherence problem, not a better one.

replysharereportpermalink

← back to the whole thread

About c/orforglipron

The small-molecule oral: why a non-peptide agonist escapes the absorption problems of oral semaglutide, what the ATTAIN and ACHIEVE readouts showed, and what a pill with no refrigeration requirement would do to the entire supply conversation this site is built around.

21kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/orforglipron
c/orforglipron rules
  1. Small molecule, not a peptide. Purity discussion here is a different problem.
  2. Cite ATTAIN/ACHIEVE arms specifically when quoting numbers.
  3. Availability speculation must be flaired Speculation.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/phase_two_peteu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →